Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Anidulafungin (Eraxis) vs Macimorelin (Macrilen)
An educational, source-based comparison of Anidulafungin (Eraxis) and Macimorelin (Macrilen) — how each peptide works, what it's researched for, and what to know before going deeper.
Echinocandin lipopeptide for invasive Candida infections.
Semisynthetic lipopeptide that non-competitively inhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesis in Candida and Aspergillus species.
- Candidemia and other invasive candidiasis
- Esophageal candidiasis
- • FDA-approved.
- • No dose adjustment for renal/hepatic impairment.
- • Infusion-related reactions possible.
Oral ghrelin agonist for diagnosing adult growth hormone deficiency.
Oral ghrelin receptor (GHSR-1a) agonist that stimulates pituitary GH release; peak GH response is measured to evaluate adult GH deficiency.
- Diagnostic test for adult GH deficiency
- • FDA-approved.
- • Avoid with QT-prolonging drugs.
- • Hold strong CYP3A4 inducers prior to test.
Anidulafungin (Eraxis) vs Macimorelin (Macrilen) — Key differences
- Class: Anidulafungin (Eraxis) is classified as Echinocandin · Antifungal, while Macimorelin (Macrilen) is GH Secretagogue · Diagnostics.
- Primary research focus: Anidulafungin (Eraxis) — candidemia and other invasive candidiasis; Macimorelin (Macrilen) — diagnostic test for adult gh deficiency.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Diagnostics.